Kalaris Therapeutics CFO Matthew Gall Resigns, Effective April 14

Benzinga Newsdesk www.benzinga.com Neutral 92.4%

Neg 0% Neu 92.4% Pos 0%

https://www.sec.gov/ix?doc=/Archives/edgar/data/1754068/000119312526151215/d108368d8k.htm

Comments

No comments yet. Be the first!